# A Study to Evaluate the Safety and Efficacy of MEDI6012 in Acute ST Elevation Myocardial Infarction

Study · id `cardio:ct-nct03578809` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03578809](<https://clinicaltrials.gov/study/NCT03578809>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03578809

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 593 participants.

## Technical summary

Registry record NCT03578809. Randomized; triple masking; primary purpose treatment. Start 2018-06-05 (actual); primary completion 2021-01-18 (actual). Results posted on 2022-02-09.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 593 participants (enrolled count; ClinicalTrials.gov record NCT03578809, source copy `cardio:ctgov-nct03578809-2022-02-09`, retrieved 2026-10-26)
- Started: 2018-06-05 (actual) (ClinicalTrials.gov record NCT03578809, source copy `cardio:ctgov-nct03578809-2022-02-09`, retrieved 2026-10-26)
- Primary completion: 2021-01-18 (actual) (ClinicalTrials.gov record NCT03578809, source copy `cardio:ctgov-nct03578809-2022-02-09`, retrieved 2026-10-26)
- Completion: 2021-01-18 (actual) (ClinicalTrials.gov record NCT03578809, source copy `cardio:ctgov-nct03578809-2022-02-09`, retrieved 2026-10-26)
- Results first posted: 2022-02-09 (ClinicalTrials.gov record NCT03578809, source copy `cardio:ctgov-nct03578809-2022-02-09`, retrieved 2026-10-26)
- Countries: Brazil; Czechia; Hungary; Israel; Netherlands; Poland; Russia; Slovakia; Spain; United Kingdom (ClinicalTrials.gov record NCT03578809, source copy `cardio:ctgov-nct03578809-2022-02-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03578809-2022-02-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Evaluate the Safety and Efficacy of MEDI6012 in Acute ST Elevation Myocardial Infarction
- Acronym: REAL-TIMI 63B
- Condition: ST Elevation Myocardial Infarction
- Intervention (Biological): MEDI6012
- Intervention (Other): Placebo
- Lead sponsor: MedImmune LLC
- Lead sponsor class: INDUSTRY
- Collaborator: The TIMI Study Group
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry lists this organization as the lead sponsor: MedImmune LLC (`cardio:org-medimmune-llc`)
- Registry lists this organization as a collaborator: The TIMI Study Group (`cardio:org-the-timi-study-group`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Randomized, Placebo-Controlled Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Lecithin Cholesterol Acyltransferase in Acute ST-Segment-Elevation Myocardial Infarction: Results of REAL-TIMI 63B (`cardio:pubmed-36039762`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 857048fcfbe6db60a2d547f15ca5ee04e6d041aaedad8f2e5ff8d4332283ac03
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
